{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:35:58Z","timestamp":1794447358579,"version":"4.9.1"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2012,9,15]]},"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p>\n                    This phase II, randomised, double-blind, multicentre study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00930982\">NCT00930982<\/jats:ext-link>\n                    ) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis.\n                  <\/jats:p>\n                  <jats:p>\n                    Adults who were culture positive for pre-defined potential respiratory pathogens (including\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and\n                    <jats:italic>Haemophilus influenzae<\/jats:italic>\n                    ) were randomised to ciprofloxacin DPI 32.5 mg or placebo administered twice daily for 28 days (with 56 days of follow-up). Bacterial density in sputum (primary end-point), pulmonary function tests, health-related quality of life and safety were monitored throughout the study.\n                  <\/jats:p>\n                  <jats:p>\n                    60 subjects received ciprofloxacin DPI 32.5 mg and 64 received placebo. Subjects on ciprofloxacin DPI had a significant reduction (p&lt;0.001) in total sputum bacterial load at the end of treatment (-3.62 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU\u00b7g\n                    <jats:sup>\u22121<\/jats:sup>\n                    (range -9.78\u20135.02 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU\u00b7g\n                    <jats:sup>\u22121<\/jats:sup>\n                    )) compared with placebo (-0.27 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU\u00b7g\n                    <jats:sup>\u22121<\/jats:sup>\n                    (range -7.96\u20135.25 log\n                    <jats:sub>10<\/jats:sub>\n                    CFU\u00b7g\n                    <jats:sup>\u22121<\/jats:sup>\n                    )); the counts increased thereafter. In the ciprofloxacin DPI group, 14 (35%) out of 40 subjects reported pathogen eradication at end of treatment\n                    <jats:italic>versus<\/jats:italic>\n                    four (8%) out of 49 in the placebo group (p=0.001). No abnormal safety results were reported and rates of bronchospasm were low.\n                  <\/jats:p>\n                  <jats:p>Ciprofloxacin DPI 32.5 mg twice daily for 28 days was well tolerated and achieved significant reductions in total bacterial load compared with placebo in subjects with non-cystic fibrosis bronchiectasis.<\/jats:p>","DOI":"10.1183\/09031936.00071312","type":"journal-article","created":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T15:31:43Z","timestamp":1348846303000},"page":"1107-1115","source":"Crossref","is-referenced-by-count":182,"title":["Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study"],"prefix":"10.1183","volume":"41","author":[{"given":"Robert","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Greville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Alder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2012,9,27]]},"reference":[{"key":"2024102021283265000_41.5.1107.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2209"},{"key":"2024102021283265000_41.5.1107.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00003709"},{"key":"2024102021283265000_41.5.1107.3","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.1.15"},{"key":"2024102021283265000_41.5.1107.4","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2011.217"},{"key":"2024102021283265000_41.5.1107.5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/COPD.S6133","article-title":"The pathophysiology of bronchiectasis","volume":"4","author":"King","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024102021283265000_41.5.1107.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0776"},{"key":"2024102021283265000_41.5.1107.7","doi-asserted-by":"publisher","DOI":"10.4104\/pcrj.2011.00007"},{"key":"2024102021283265000_41.5.1107.8","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2007.0652"},{"key":"2024102021283265000_41.5.1107.9","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00105211"},{"key":"2024102021283265000_41.5.1107.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.2.331"},{"key":"2024102021283265000_41.5.1107.11","unstructured":"Gupta A Tarara T Miller D . A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections. Am Assoc Pharmaceut Scientists J 2011; 13 (S2): abstract R6156."},{"key":"2024102021283265000_41.5.1107.12","first-page":"G50","article-title":"Ciprofloxacin PulmoSphere\u00ae inhalational powder: a healthy volunteer study.","volume":"177","author":"Stass","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102021283265000_41.5.1107.13","first-page":"p. 300.","article-title":"Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in adult patients with cystic fibrosis.","volume":"43","author":"Stass","year":"2008","journal-title":"Paediatr Pulmonol"},{"key":"2024102021283265000_41.5.1107.14","first-page":"A3105","article-title":"Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial","volume":"183","author":"Tokimatsu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102021283265000_41.5.1107.15","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9607083"},{"key":"2024102021283265000_41.5.1107.16","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.6.1321"},{"key":"2024102021283265000_41.5.1107.17","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcr184"},{"key":"2024102021283265000_41.5.1107.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0756OC"},{"key":"2024102021283265000_41.5.1107.19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.4.9906120"},{"key":"2024102021283265000_41.5.1107.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.11.008"},{"key":"2024102021283265000_41.5.1107.21","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.5.366"},{"key":"2024102021283265000_41.5.1107.22","doi-asserted-by":"publisher","DOI":"10.1586\/17476348.2.4.479"},{"key":"2024102021283265000_41.5.1107.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.3_suppl.118S"},{"key":"2024102021283265000_41.5.1107.24","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050513"},{"key":"2024102021283265000_41.5.1107.25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-0490"},{"key":"2024102021283265000_41.5.1107.26","first-page":"CD001021","article-title":"Inhaled antibiotics for long-term therapy in cystic fibrosis","volume":"3","author":"Ryan","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00071312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:40:05Z","timestamp":1740361205000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00071312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,4,30]]},"published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1183\/09031936.00071312"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00071312","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958970.793466073","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}